P30GM149368
Project Grant
Overview
Grant Description
Oklahoma Center for Respiratory and Infectious Diseases - Overall Project Summary
This COBRE Phase III application seeks support to develop sustainable research facilities to further enhance a nationally competitive multi-institutional biomedical research center—the Oklahoma Center for Respiratory and Infectious Diseases (OCRID). Established in 2013 through the Phase I COBRE grant and sustained in 2018 through the Phase II COBRE grant, OCRID has become a focal point for expanding respiratory infectious disease research in Oklahoma.
Based at Oklahoma State University (OSU), OCRID investigators come from major research institutions across the state of Oklahoma, including 9 colleges at OSU and the University of Oklahoma, as well as an independent research institute, the Oklahoma Medical Research Foundation. As the first COBRE grants ever received by OSU, the Phase I and Phase II awards have had a transformative effect on the landscape of respiratory infectious disease research in Oklahoma.
OCRID engages in critical research on respiratory infectious diseases with a focus on influenza virus, respiratory syncytial virus, respiratory bacterial and fungal infections, and now COVID-19. The interdisciplinary projects in OCRID cover therapeutics, vaccines, diagnostics, disease pathogenesis, nutrition, and bioengineering.
Building on the success of the Phase I and Phase II awards, the overall objective of this Phase III COBRE application is to further sustain a research center of excellence in the field of respiratory infectious diseases through the continued development of research facilities in a collaborative environment.
Aim 1 will continue to develop research core facilities with cutting-edge technologies and transform them into sustainable institutional core facilities. We will continue to provide core expertise and services to COBRE projects and other investigators, modernize the established cores, develop state-of-the-art new technologies to meet the needs of the center investigators, and broaden core services. A strategic plan to complete the transition of these core facilities into self-sustained institutional research facilities includes cost recovery, institutional support, securing equipment, resource and technology, and collaborative grants, industry partners, and philanthropy.
Aim 2 will further enhance the research environment to sustain impactful research via a pilot projects program and interinstitutional collaborations. We will continue to expand the critical mass of multidisciplinary investigators in the thematic area of respiratory infectious diseases by nurturing junior investigators and redirecting established investigators into respiratory infectious disease research via a pilot projects program and hiring new tenure-track faculty members whose research is within the focus of the center. We will also continue to provide research and career development activities and promote interinstitutional collaborations in Oklahoma via a research seminar series, work-in-progress and journal club meetings, an annual respiratory and infectious disease research symposium, and the development of multi-investigator grant applications.
This COBRE Phase III application seeks support to develop sustainable research facilities to further enhance a nationally competitive multi-institutional biomedical research center—the Oklahoma Center for Respiratory and Infectious Diseases (OCRID). Established in 2013 through the Phase I COBRE grant and sustained in 2018 through the Phase II COBRE grant, OCRID has become a focal point for expanding respiratory infectious disease research in Oklahoma.
Based at Oklahoma State University (OSU), OCRID investigators come from major research institutions across the state of Oklahoma, including 9 colleges at OSU and the University of Oklahoma, as well as an independent research institute, the Oklahoma Medical Research Foundation. As the first COBRE grants ever received by OSU, the Phase I and Phase II awards have had a transformative effect on the landscape of respiratory infectious disease research in Oklahoma.
OCRID engages in critical research on respiratory infectious diseases with a focus on influenza virus, respiratory syncytial virus, respiratory bacterial and fungal infections, and now COVID-19. The interdisciplinary projects in OCRID cover therapeutics, vaccines, diagnostics, disease pathogenesis, nutrition, and bioengineering.
Building on the success of the Phase I and Phase II awards, the overall objective of this Phase III COBRE application is to further sustain a research center of excellence in the field of respiratory infectious diseases through the continued development of research facilities in a collaborative environment.
Aim 1 will continue to develop research core facilities with cutting-edge technologies and transform them into sustainable institutional core facilities. We will continue to provide core expertise and services to COBRE projects and other investigators, modernize the established cores, develop state-of-the-art new technologies to meet the needs of the center investigators, and broaden core services. A strategic plan to complete the transition of these core facilities into self-sustained institutional research facilities includes cost recovery, institutional support, securing equipment, resource and technology, and collaborative grants, industry partners, and philanthropy.
Aim 2 will further enhance the research environment to sustain impactful research via a pilot projects program and interinstitutional collaborations. We will continue to expand the critical mass of multidisciplinary investigators in the thematic area of respiratory infectious diseases by nurturing junior investigators and redirecting established investigators into respiratory infectious disease research via a pilot projects program and hiring new tenure-track faculty members whose research is within the focus of the center. We will also continue to provide research and career development activities and promote interinstitutional collaborations in Oklahoma via a research seminar series, work-in-progress and journal club meetings, an annual respiratory and infectious disease research symposium, and the development of multi-investigator grant applications.
Awardee
Funding Goals
THE NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) SUPPORTS BASIC RESEARCH THAT INCREASES OUR UNDERSTANDING OF BIOLOGICAL PROCESSES AND LAYS THE FOUNDATION FOR ADVANCES IN DISEASE DIAGNOSIS, TREATMENT, AND PREVENTION. NIGMS ALSO SUPPORTS RESEARCH IN SPECIFIC CLINICAL AREAS THAT AFFECT MULTIPLE ORGAN SYSTEMS: ANESTHESIOLOGY AND PERI-OPERATIVE PAIN, CLINICAL PHARMACOLOGY ?COMMON TO MULTIPLE DRUGS AND TREATMENTS, AND INJURY, CRITICAL ILLNESS, SEPSIS, AND WOUND HEALING.? NIGMS-FUNDED SCIENTISTS INVESTIGATE HOW LIVING SYSTEMS WORK AT A RANGE OF LEVELSFROM MOLECULES AND CELLS TO TISSUES AND ORGANSIN RESEARCH ORGANISMS, HUMANS, AND POPULATIONS. ADDITIONALLY, TO ENSURE THE VITALITY AND CONTINUED PRODUCTIVITY OF THE RESEARCH ENTERPRISE, NIGMS PROVIDES LEADERSHIP IN SUPPORTING THE TRAINING OF THE NEXT GENERATION OF SCIENTISTS, ENHANCING THE DIVERSITY OF THE SCIENTIFIC WORKFORCE, AND DEVELOPING RESEARCH CAPACITY THROUGHOUT THE COUNTRY.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Stillwater,
Oklahoma
740781016
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 199% from $1,101,147 to $3,288,387.
Oklahoma State University was awarded
OCRID Phase III: Enhancing Respiratory Infectious Disease Research
Project Grant P30GM149368
worth $3,288,387
from the National Institute of General Medical Sciences in July 2023 with work to be completed primarily in Stillwater Oklahoma United States.
The grant
has a duration of 5 years and
was awarded through assistance program 93.859 Biomedical Research and Research Training.
The Project Grant was awarded through grant opportunity Limited Competition: Centers of Biomedical Research Excellence (COBRE) Phase III - Transitional Centers (P30 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 9/5/25
Period of Performance
7/5/23
Start Date
6/30/28
End Date
Funding Split
$3.3M
Federal Obligation
$0.0
Non-Federal Obligation
$3.3M
Total Obligated
Activity Timeline
Subgrant Awards
Disclosed subgrants for P30GM149368
Transaction History
Modifications to P30GM149368
Additional Detail
Award ID FAIN
P30GM149368
SAI Number
P30GM149368-716637017
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NS00 NIH National Institute of General Medical Sciences
Funding Office
75NS00 NIH National Institute of General Medical Sciences
Awardee UEI
NNYDFK5FTSX9
Awardee CAGE
0U784
Performance District
OK-03
Senators
James Lankford
Markwayne Mullin
Markwayne Mullin
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Institute of General Medical Sciences, National Institutes of Health, Health and Human Services (075-0851) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,101,147 | 100% |
Modified: 9/5/25